Clinical Advisory Board

Bionor´s Clinical Advisory Board consists of prominent experts within the fields of HIV/AIDS, functional HIV cure and immunology.

Jürgen Rockstroh, MD, PhD

Jürgen Rockstroh, MD, PhD

Professor, Oberarzt an der Medizinischen Universitätsklinik, Bonn-Venusberg

Chairman of the Clinical Advisory Board

Jürgen Rockstroh is a Professor of Medicine at the University of Bonn and has been Head of a HIV outpatient clinic since 1995. He is an investigator from various protease inhibitor studies and has considerable experience with various antiretroviral drug regimens and clinical trialsfor treatment of HIV and hepatitis co-infection. He has been elected chair of the KAAD (German Clinical AIDS Working Group) since 1998.Jürgen Rockstroh's department treats the world's largest cohort of HIV-infected haemophiliacs. His research interests encompass protease inhibitor therapy, including dual regimens, the course of HIV disease in haemophiliacs, HIV/HCV co-infection, and cytokines and apoptosis before and after antiretroviral therapy. He is a prolific speaker at international conferences and has published more than
100 articles and book chapters.

Angus Dalgleish MD FRCP, FRACP, FRCPath, FMedSci

Angus Dalgleish MD FRCP, FRACP, FRCPath, FMedSci

Professor, St. George's University, London

Angus Dalgleish has been Professor of Oncology at St. George's University of London since 1991.  He has been involved with HIV research since the first descriptions of AIDS. Working as a clinical fellow with Robin Weiss he described the use of CD4 as the main receptor for HIV and was the first to associate HIV with the outbreak of SLIM disease in Uganda. His main interest is the pathogenesis of HIV that has to induce immune activation before the infection can proceed to clinical AIDS. His group was the first to suggest that the C5 region of gp120 could act as if it were a foreign transplant antigen (alloepitope) and induce the activation that precedes AIDS and also to suggest it as a potential therapeutic target. Professor Dalgleish has also pioneered the use of cancer vaccines and is principal of the Cancer Vaccine Institute and has been principal and clinical investigator on numerous vaccine trials. He has published over 300 peer reviewed papers and co-edited five books including HIV and the New Viruses and Tumor Immunology, as well as numerous book chapters.

Steven G. Deeks, M.D.

Steven G. Deeks, M.D.

Professor of Medicine in Residence at the University of California, San Francisco and a faculty member in the Positive Health Program (AIDS Program) at San Francisco General Hospital.

Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is an expert on the role of chronic inflammation in untreated and treated HIV disease. His research has several linked objectives, including “persistent inflammation during therapy, novel therapeutic interventions to reduce chronic inflammation and the size of the latent reservoir”. Dr. Deeks has published over 300 peer-review articles, editorials and invited reviews. He is the principle investigator of NIH-funded international collaboration aimed at developing therapeutic interventions to cure HIV infection (DARE). Dr. Deeks is the co-chair of the “Towards an HIV Cure” International Working Group and member of the Office of AIDS Research Advisory Council (ORAC). He is a member of the Department on Health and Human Services Panel on Antiretroviral Guidelines. In addition to research, Dr. Deeks maintains a primary care clinic for HIV infected patients.

Christine Katlama, M.D.

Christine Katlama, M.D.

Professor of Infectious Diseases at Pierre and Marie Curie University in Paris.

She is head of the AIDS clinical care unit at Pitié Salpetriere Hospital and co-director of the HIV clinical epidemiology unit at Pierre Louis Institute Paris Sorbonne. Professor Katlama is also actively involved in the ANRS (French National Agency for HIV Research) and heads its antiretroviral strategy group. She cofunded the ORVVACS network towards HIV vaccine and Cure. Christine Katlama has worked with HIV since 1982 and was involved in the HIV-2 discovery in 1986. Her group first demonstrated the impact of HAART on immune reconstitution and works extensively in the field of new drugs, viral resistance, novel antiretroviral strategies and HIV cure. Christine Katlama is actively involved in the NEAT European Network and since 2011, in the IAS HIV cure initiative. Professor Katlama is a past President of EACS and is currently in charge of the EACS educational programme, organizing the EACS Advanced HIV Course and the ECRECO Clinical Research Course. She is a member of numerous international HIV advisory boards for pharmaceutical companies and is on the editorial boards of several journals, including HIV Medicine and AIDS, with over 400 articles on HIV clinical science to her name.

Daniel Kuritzkes, M.D.

Daniel Kuritzkes, M.D.

Professor of Medicine at Harvard Medical School and Division Chief at an affiliated academic teaching hospital.

He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School. Dr. Kuritzkes has published more than 300 research articles, reviews and book chapters. He is a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy, has served on NIH editorial boards and committees, and previously served as Chair of the HIV Medicine Association Board of Directors. Dr. Kuritzkes has chaired several multicenter HIV studies, and he currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group. Dr. Kuritzkes is an Associate Editor of the Journal of Infectious Diseases. His research interests focus on resistance to antiretroviral drugs, viral fitness, viral tropism, HIV-1 persistence and eradication.
Dag Kvale, M.D, PhD

Dag Kvale, M.D, PhD

Professor, Oslo University Hospital, Oslo, Norway

Dag Kvale is Professor of Medicine at the Department of Infectious Diseases Ullevål at Oslo University Hospital. He is originally trained as a mucosal immunologist but started clinical education with HIV-infected patients in 1988. Kvale has been PI on two of the Bionor Immuno-sponsored studies with therapeutic HIV vaccines, one (Vacc-4x) which formed the basis for the extension of the Vacc-4x study into the ongoing multicentre trial. With Bionor Immuno as one of several key partners, Kvale also heads two grants from Research Council of Norway to investigate optimization of peptide-based regimen and to conduct clinical studies on alternative immune modulation in patients with untreated chronic HIV infection, respectively. Kvale has published about 80 scientific papers on immunological topics and HIV/AIDS.

Giuseppe Pantaleo, M.D.

Giuseppe Pantaleo, M.D.

Professor of medicine

Dr. Pantaleo is the Chief of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. During the past fifteen years, Professor Pantaleo’s research has been focused on the delineation of the immunopathogenesis of HIV infection and of other viral infections such as cytomegalovirus and hepatitis C virus. His research activities have been focused on human T cell cloning, human T cell phenotypic and functional analysis, T cell activation, differentiation and memory, immunopathogenesis of HIV infection, HIV distribution in different anatomic compartments, antiretroviral therapy, immune reconstitution after antiretroviral therapy, immune-based therapeutic strategies and vaccines. Professor Pantaleo is author and co-author of more than 200 publications in international scientific journals.

Barry S. Peters, MBBS, DFFP, MD, FRCP

Barry S. Peters, MBBS, DFFP, MD, FRCP

Kings College London

Dr Peters is Head of the Academic Unit of HIV & STDs at the Guys & St Thomas' site of Kings College London. He has 20 years of clinical experience of managing people with HIV infection, he has a large NHS clinical HIV practice, and co-authors the British HIV Adult Treatment Guidelines for adults with HIV infection. He set up and runs a clinical trials unit for HIV therapies and HIV vaccines, based at St Thomas' Hospital. The unit has experience of HIV vaccine design, both immunotherapeutic and prophylactic, and amongst several studies is a recently completed large Phase 2 study on a prophylactic DNA HIV vaccine, sponsored by IAVI.Dr Peters was attached to the HIV vaccine unit at the WHO during 2006 for 6 months, and helped develop Phase 2B designs, in conjunction with IAVI, NIH, CDC etc.

Richard Pollard, M.D

Richard Pollard, M.D

Professor, University of California, Sacramento, USA

Dr. Pollard is a professor of Microbiology and Internal Medicine at the University of California. He has also been Chief, Division of Infectious Diseases since 2002. Dr Pollard’s research interests are focused on the pathogenesis of HIV infection and complicating viruses. His laboratory conducts studies of human immune responses to HIV in patients on clinical trials using antiretrovirals or immunomodulating agents. The laboratory also conducts studies measuring immune responses of mucosal tissues such as those from gut biopsies and comparing those to those from the peripheral blood compartment. The laboratory is also focusing on differing immune responses in minority subject and in women. He has been an author on more than 200 scientific publications.

Lars Østergaard, chief physician, MD, PhD, DMSc

Lars Østergaard, chief physician, MD, PhD, DMSc

Professor of infectious diseases, University of Aarhus, and Head of Dept. of Infectious Diseases, Aarhus University Hospital, Denmark

Prof. Østergaard has been principal investigator in several international research projects with up to 50 active researchers. He has been responsible for more than 200 papers in peer reviewed scientific journals. He is scientific reviewer for the Lancet,British Medical Journal, Journal of Infectious Diseases, AIDS, and Clinical Infectious Diseases. He has filed several patent applications and is co-founder of the biotech companies Enfutech and SKAU vaccines.